Montreux Equity Partners has promoted Dr. Michael Matly to managing director. Matly, who joined the investment firm in 2012 as a principal, is the founding advisor to Rock Health.
SAN FRANCISCO–(BUSINESS WIRE)–Montreux Equity Partners, a private investment firm focused on high growth, commercial stage companies, today announced the appointment of Michael Matly, MD to managing director. In his new role, Dr. Matly will be part of the leadership team for Montreux’s late stage investment decisions and building a proprietary pipeline of target investments in the healthcare and technology sectors.
Dr. Matly joined Montreux as a principal in 2012. Dr. Matly has led a number of recent investments for Montreux including MINDBODY (NASDAQ: MB) and Kareo. He currently serves on the boards of Kareo, Pure Life Renal and Pulmonx. Dr. Matly is also the founding advisor to Rock Health, a leading digital health incubator and venture fund based in San Francisco, and is recognized as an industry thought leader, contributing to leading publications such as VentureBeat.
“We are thrilled to announce Michael’s promotion,” said Dan Turner, founder and managing director of Montreux Equity Partners. “Michael has proven to be a leader in our firm and in the investment community; demonstrating outstanding leadership and investment judgment, he will continue to play an integral role in the future of Montreux as we expand our team and our portfolio of market leading investments.”
Prior to joining Montreux, Dr. Matly led business development at the Mayo Clinic Center for Innovation, where he was responsible for new venture incubation and product development. He also served as the co-founder and CEO of HAYATI Healthcare, a patient financing company. Dr. Matly completed his M.D. from the Mayo Clinic, M.B.A from Harvard Business School, and B.S. from Cornell University.
About Montreux Equity Partners
Montreux is dedicated to making growth capital investments in category-leading companies with products, technologies and services. Since 1993, Montreux has invested in more than 50 companies including MINDBODY (NASDAQ: MB), Glaukos (NYSE: GKOS), MAKO Surgical (acquired by Stryker), SkinMedica (acquired by Allergan), Great Lakes Health Plan (acquired by United Healthcare), Cerexa (acquired by Forest Laboratories), Novacardia (acquired by Merck), and Peninsula (acquired by Johnson & Johnson). At the time of investment, a company will have $10 to $50 million in revenues. Montreux typically invests $10 to $20 million per company to fuel product expansion, new market entry, and strategic acquisitions. Montreux is based in San Francisco, CA and is currently investing out of its fifth fund. For more information, visit www.mepvc.com.